Tiziana Life Sciences PLC Tiziana Life Sciences to Host Investor Update Call
December 01 2020 - 2:00AM
RNS Non-Regulatory
TIDMTILS
Tiziana Life Sciences PLC
01 December 2020
Tiziana Life Sciences to Host Investor Update Call
on 2 December 2020 at 4:15 p.m. ET
NEW YORK and LONDON - 1 December 2020 (GLOBE NEWSWIRE) - Tiziana
Life Sciences plc (NASDAQ: TLSA) ("Tiziana" or the "Company"), a
biotechnology company focused on innovative therapeutics for
oncology, inflammation and infectious diseases, today announced its
CEO and CSO Dr. Kunwar Shailubhai will host a conference call on
Wednesday, 2 December 2020 at 4:15 p.m. ET to provide updates on
the Company. Dr Shailubhai will provide updates on the Company's
proposed move from AIM to the Standard Segment of the Main Market
of the London Stock Exchange, ongoing clinical trials, as well as
other recent developments in Tiziana Life Sciences.
Date: Wednesday, 2 December 2020
Time: 4:15 p.m. Eastern Time
Live Call: +1-877-425-9470 (U.S. Toll-Free) or +1-201-389-0878 (International)
Webcast: http://public.viavid.com/index.php?id=142634
For interested individuals unable to join the conference call, a
dial-in replay of the call will be available until 16 December 2020
and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or
+1-412-317-6671 (International) and entering replay pin number:
13713850.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules to
treat human disease in oncology and immunology. In addition to
Milciclib, the Company is also developing Foralumab for liver
diseases. Foralumab is the only fully human anti-CD3 monoclonal
antibody in clinical development in the world. This Phase 2
compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as nonalcoholic steatohepatitis
(NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes
(T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
United States Investors:
Dave Gentry Office 1 800 RED CHIP (733
RedChip Companies Inc. 2447)
Cell 407-491-4498 (USA)
dave@redchip.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABMBLTMTAJBPM
(END) Dow Jones Newswires
December 01, 2020 02:00 ET (07:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Nov 2023 to Nov 2024